| abstract |
The present invention relates to binding components specific for interleukin 1 receptor 1 (IL-1R1), in particular antibody molecules. For example, against IL-1R1, which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds IL-1R1 with a K D of 10 pM or less, as measured by Kinexa ™. It relates to a specific isolated binding component. Binding components are particularly useful for treating disorders mediated by IL-1R1, including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD). |